Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (482)	6/18/2004 2:29:16 PM
From: tuck	Read Replies (3) of 496

>>I think glfd's commercial strategy is to go into markets where propofol can't be used. Head to head, aquavan is unlikely to do well against generic propofol. So a sound strategy imo.<< Are the non-propofol markets what management is talking about when they talk of Aquavan's market opportunity (.5 billion, if memory serves)? How important, then, are the trials versus Midazolam? Are there generics coming for that, too? I'll go dig if need be, but if y'all have the answers off of the top of your heads, I'd appreciate being saved the trouble. OT -- been digging a bit on Corgentech and Cytokinetics. See threads; looking for help there, too, though not expecting any from Harry. TIA & Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next